AI Drug Discovery
How models can help search chemical, genetic, and biological spaces faster than traditional research methods.
Major hub
AI + Medicine
How artificial intelligence is accelerating drug discovery, diagnosis, clinical trials, and the future of rare disease research.
AI without robot cliches
Where AI may matter for rare disease
The promise is real, but the work still depends on careful science, validated models, useful data, and attention to families.
Biological Foundation Models
How frontier models trained on biological data may help scientists understand proteins, genes, cells, and disease mechanisms.
AI in Rare Disease Diagnosis
How AI may help shorten the diagnostic odyssey through genetic analysis, medical records, imaging, and pattern recognition.
Digital Twins and Trial Design
How simulated models of patients or disease biology could help design better trials, especially for small rare disease populations.
Automated Labs
How robotics, AI agents, and lab automation could speed up design-make-test-learn cycles.
AI and the Future of Care
How AI's economic disruption could be redirected toward human support, disability care, special education, and community-based services.
AI + medicine analysis
AI + Rare Disease
What AI Drug Discovery Could Mean for Rare Disease Families
AI drug discovery is entering a new phase: not just better software, but a new industrial stack linking frontier models, pharma data, robotics, and real experiments.
Why it matters: Rare disease research often starts with small datasets, limited funding, urgent timelines, and difficult trial design. AI-linked discovery systems could help researchers generate stronger candidates and better experiments faster, but families should watch for clinical validation, access, manufacturing, and clear evidence rather than hype.
AI + Rare DiseaseAI Drug DiscoveryAutonomous Labs
Source: GENEration Hope editorial analysis
ReadAccess and Policy
The AI Revolution Should Also Be a Care Revolution
If AI unlocks new productivity, rare disease families should be part of the conversation about where that value goes: care, support, education, and dignity.
Why it matters: Rare disease families live with care needs that are often invisible to economic debates. The future should make those needs more visible, not less.
Access and PolicyFuture of CareCare
Source: Founder note
ReadTrial Updates
How AI Could Change Clinical Trials for Ultra-Rare Disorders
Ultra-rare trials are often small, fragile, and difficult to interpret. AI may help researchers design studies that are more realistic without lowering the bar for evidence.
Why it matters: Ultra-rare trials need rigorous design even when traditional large studies are difficult or impossible.
Trial UpdatesClinical TrialsDigital Twins
Source: GENEration Hope editorial analysis
ReadAI + Rare Disease
Could AI Help Solve the Rare Disease Diagnosis Odyssey?
AI may help shorten the diagnostic odyssey, but only if it strengthens clinical judgment instead of adding another opaque layer to an already exhausting process.
Why it matters: Shortening the time to diagnosis can change care planning, research participation, and access to support.
AI + Rare DiseaseDiagnosisGenomics
Source: GENEration Hope editorial analysis
ReadResearch Milestones
What Are Biological Foundation Models?
Biological foundation models are trained on the raw languages of life, and researchers are watching to see whether they can make biology more searchable, predictable, and useful.
Why it matters: These models may help scientists reason across genes, proteins, cells, and disease mechanisms, but they must be tested carefully in real biology.
Research MilestonesFoundation ModelsBiology
Source: GENEration Hope editorial analysis
Read